SynthesisFrontiers in oncology2025
Non-systemic treatment of metastatic kidney cancer: systematic review and a case report.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: To date, there is insufficient literature on the local treatment options for metastatic renal cell carcinoma (mRCC). Various options, such as metastasectomy, thermal ablation, and stereotactic body radiotherapy, have gained attention for their potential to improve survival and quality of life in selected patients' groups. This systematic review analyzes the effectiveness of these approaches and highlights their potential to improve survival outcomes. By analyzing survival outcomes, this review aims to guide future research, thereby enhancing clinical decision-making. Materials and methods: A systematic review of studies published since 2009 was conducted, following PRISMA guidelines. Relevant articles were identified from PubMed and ScienceDirect databases, using search terms related to mRCC and non-systemic treatment. The review was not registered, and a protocol was not prepared. Additionally, a case report documenting the successful use of cryoablation in controlling metastases of kidney cancer was included to illustrate clinical relevance. Results: Thirteen studies met the inclusion criteria. Complete metastasectomy demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to incomplete or no metastasectomy. Stereotactic body radiotherapy (SBRT) and other forms of radiotherapy provided effective palliation and durable disease control. Conclusions: This systematic review highlights the potential survival benefits for mRCC patients with the use of different local treatment modalities, especially in terms of complete metastasectomy. The findings show the need for continued research to optimize local treatment strategies, along with improving the quality of life for metastatic kidney cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.